MANE — Veradermics, Inc
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1827635 ·
Last close
$124.39
Market Cap
$5.25B
52W High
$156.63
52W Low
$32.00
ADV30
700,058
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 0 | — | -29,553,000 | -23,502,000 | 825,735,000 | 319,333,000 | 12,122,000 |
| Mar 2026 | 0 | — | -29,713,000 | -27,232,000 | 397,356,000 | 168,412,000 | 6,716,000 |
| Dec 2025 | 0 | — | -22,753,000 | -21,847,000 | 152,619,000 | 21,766,000 | 273,633,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-78,300,000
Investing CF
$-473,364,000
Financing CF
$862,401,000
CapEx
$-24,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.00
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-174,155,000
Inventory
—
Receivables
$1,589,000
ST Investments
$500,561,000
EBIT TTM
$-100,273,000
Pretax Income TTM
$-92,684,000
Interest Exp TTM
$0
Analysts
6
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -71,557,000 | -69,995,000 | 152,619,000 | 273,633,000 | -121,014,000 | -71,602,000 |
| Dec 2024 | 0 | -26,384,000 | -26,488,000 | 55,535,000 | 104,015,000 | -48,480,000 | -23,688,000 |
| Dec 2023 | 0 | -17,324,000 | -16,490,000 | 17,562,000 | 39,804,000 | -22,242,000 | -13,510,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$825,735,000
Forward EPS
$-2.58
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $100.00 · spot: $124.39 · call volume: 107 · put volume: 18Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LQDA | Liquidia Corp | $5.10B | $56.63 | — |
| ERAS | Erasca, Inc. | $4.99B | $14.22 | — |
| PTCT | PTC THERAPEUTICS, INC. | $4.87B | $58.33 | — |
| COGT | Cogent Biosciences, Inc. | $4.83B | $27.74 | — |
| LGND | LIGAND PHARMACEUTICALS INC | $5.72B | $286.94 | — |
News headlines (Yahoo Finance, 1h cache)
Veradermics to Present at the Jefferies Global Healthcare Conference in London
2026-11-12 21:30 · Yahoo
Veradermics: Q3 Earnings Snapshot
2026-11-10 22:49 · Yahoo
Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
2026-11-10 12:30 · Yahoo
Veradermics stock rises on 12-month hair growth trial data
2026-11-09 18:04 · Yahoo
Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
2026-11-08 23:00 · Yahoo
Veradermics (MANE) Late Stage Trial Narrative Keeps Undervalued View Alive
2026-11-06 15:13 · Yahoo
Connecticut Innovations Generates Record Breaking $51.4 Million in Venture Proceeds in Q1 FY27
2026-11-05 14:00 · Yahoo
Why This Hair Restoration Biotech's Shares Are Soaring
2026-10-25 13:20 · Yahoo
Could This Pill Be a Game Changer for Hair Loss? Veradermics Reports Major Breakthrough
2026-10-22 10:24 · Yahoo
Veradermics’ stock up on male hair loss trial success
2026-10-19 17:18 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.